TVTX

SEC source: 0001415889-25-003063 · form4-02042025_080209.xml · nonDerivative · entry 1

Heerma Peter · CIK 0001789617 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,874

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001415889-25-003062 · form4-02042025_080206.xml · derivative · entry 3

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,000

Underlying: Common Stock · 58,000 shares

Expires 2035-01-31

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-25-003062 · form4-02042025_080206.xml · nonDerivative · entry 1

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,230

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001415889-25-002003 · form4-01242025_010152.xml · derivative · entry 3

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,000 shares

Expires 2026-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001415889-25-002003 · form4-01242025_010152.xml · nonDerivative · entry 2

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,000

F1 · kind: This sale was made pursuant to a written plan adopted on August 16, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on July 19, 2016, with an expiration date of July 19, 2026.

SEC source: 0001415889-25-002003 · form4-01242025_010152.xml · nonDerivative · entry 1

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-001997 · form4-01242025_010158.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,002

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001415889-25-002008 · form4-01242025_010159.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,170

F1 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F2 · balance_after: Includes 1,152 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 29, 2024.

SEC source: 0001415889-25-002006 · form4-01242025_010157.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 351,239

F1 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001415889-25-002004 · form4-01242025_010150.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,933

F1 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F2 · balance_after: Includes 737 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 29, 2024.

SEC source: 0001415889-25-002001 · form4-01242025_010141.xml · nonDerivative · entry 1

Heerma Peter · CIK 0001789617 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,374

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001415889-25-001999 · form4-01242025_010121.xml · nonDerivative · entry 1

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,730

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001415889-25-000899 · form4-01072025_120158.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,443

F2 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001415889-25-000899 · form4-01072025_120158.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,883

F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001415889-24-030210 · form4-12282024_121201.xml · derivative · entry 3

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2025-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001415889-24-030210 · form4-12282024_121201.xml · nonDerivative · entry 2

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,927

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, adopted by the Reporting Person on September 9, 2024.

F2 · price: The weighted average sale price for the transaction reported was $17.21856, and the range of prices were between $16.985 and $17.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001415889-24-030210 · form4-12282024_121201.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,927

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-027672 · form4-11262024_021145.xml · derivative · entry 3

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2025-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001415889-24-027672 · form4-11262024_021145.xml · nonDerivative · entry 2

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,927

F1 · shares: Represents the number of shares required to be sold by the Reporting Person in order to cover the tax withholding obligation and payment of the exercise price in connection with the partial exercise of a stock option granted to the Reporting Person on January 2, 2015 with an upcoming expiration date of January 2, 2025.

F2 · price: The weighted average sale price for the transaction reported was $18.3009, and the range of prices were between $18.27 and $18.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001415889-24-027672 · form4-11262024_021145.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,017

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-024795 · form4-10042024_111048.xml · derivative · entry 4

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2024-10-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001415889-24-024795 · form4-10042024_111048.xml · nonDerivative · entry 3

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,000

F1 · kind: This sale was made pursuant to a written plan adopted on March 16, 2023 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on October 8, 2014 with an expiration date of October 8, 2024.

F3 · price: The weighted average sale price for the transaction reported was $15.1547, and the range of prices were between $14.92 and $15.44. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001415889-24-024795 · form4-10042024_111048.xml · nonDerivative · entry 2

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,821

F1 · kind: This sale was made pursuant to a written plan adopted on March 16, 2023 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on October 8, 2014 with an expiration date of October 8, 2024.

F2 · price: The weighted average sale price for the transaction reported was $14.3479, and the range of prices were between $13.92 and $14.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001415889-24-024795 · form4-10042024_111048.xml · nonDerivative · entry 1

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-024117 · form4-10012024_121008.xml · derivative · entry 3

Meckler Jeffrey A · CIK 0001506916 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2024-10-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001415889-24-024117 · form4-10012024_121008.xml · nonDerivative · entry 2

Meckler Jeffrey A · CIK 0001506916 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,000

F1 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on October 8, 2014 with an expiration date of October 8, 2024.

F2 · price: The weighted average sale price for the transaction reported was $14.0581, and the range of prices were between $13.782 and $14.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001415889-24-024117 · form4-10012024_121008.xml · nonDerivative · entry 1

Meckler Jeffrey A · CIK 0001506916 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-023128 · form4-09102024_040901.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,949

F1 · kind: This sale was made pursuant to a written plan adopted March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units that vested on September 5, 2024.

SEC source: 0001415889-24-023093 · form4-09092024_090907.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,633

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001415889-24-023095 · form4-09092024_090911.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,633

F2 · kind: This sale was made pursuant to a written plan adopted March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001415889-24-023096 · form4-09092024_090913.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,455

F3 · kind: This sale was made pursuant to a written plan adopted March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001415889-24-023094 · form4-09092024_090909.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 361,975

F2 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001415889-24-023092 · form4-09092024_090904.xml · nonDerivative · entry 2

Heerma Peter · CIK 0001789617 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,958

F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001415889-24-023091 · form4-09092024_090901.xml · nonDerivative · entry 2

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,595

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001415889-24-023093 · form4-09092024_090907.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,824

F1 · kind: On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 6,750 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.

SEC source: 0001415889-24-023095 · form4-09092024_090911.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,020

F1 · kind: On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 6,750 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.

SEC source: 0001415889-24-023096 · form4-09092024_090913.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · SENIOR VICE PRESIDENT, R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,842

F1 · kind: On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 6,750 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.

F2 · balance_after: Includes 1,372 shares of Common Stock that were acquired by the Reporting Person on May 31, 2024 pursuant to the Issuer's Employee Stock Purchase Plan.

SEC source: 0001415889-24-023094 · form4-09092024_090909.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 383,100

F1 · kind: On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 32,500 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.

SEC source: 0001415889-24-023092 · form4-09092024_090904.xml · nonDerivative · entry 1

Heerma Peter · CIK 0001789617 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,149

F1 · kind: On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 6,750 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.

F2 · balance_after: Includes 3,896 shares of Common Stock that were acquired by the Reporting Person on May 31, 2024 pursuant to the Issuer's Employee Stock Purchase Plan.

SEC source: 0001415889-24-023091 · form4-09092024_090901.xml · nonDerivative · entry 1

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,085

F1 · kind: On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 6,750 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.

SEC source: 0001415889-24-022992 · form4-09052024_090901.xml · nonDerivative · entry 1

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,335

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001415889-24-012847 · form4-05102024_040530.xml · derivative · entry 2

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2034-05-07

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001415889-24-012847 · form4-05102024_040530.xml · nonDerivative · entry 1

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,000

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001415889-24-012849 · form4-05102024_040541.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2034-05-07

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001415889-24-012849 · form4-05102024_040541.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,875

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001415889-24-012851 · form4-05102024_040553.xml · derivative · entry 2

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2034-05-07

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001415889-24-012851 · form4-05102024_040553.xml · nonDerivative · entry 1

Squarer Ron · CIK 0001454001 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,875

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001415889-24-012852 · form4-05102024_040555.xml · derivative · entry 2

Williams Brinkley Ruth · CIK 0001344381 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2034-05-07

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001415889-24-012852 · form4-05102024_040555.xml · nonDerivative · entry 1

Williams Brinkley Ruth · CIK 0001344381 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,250

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001415889-24-012850 · form4-05102024_040548.xml · derivative · entry 2

Poole Sandra · CIK 0001619622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2034-05-07

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.